Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

PRPH ProPhase Labs Inc

Price (delayed)

$0.3204

Market cap

$13.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.16

Enterprise value

$27.23M

ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, ...

Highlights
The debt has contracted by 43% from the previous quarter and by 40% YoY
ProPhase Labs's equity has surged by 106% QoQ but it has shrunk by 66% YoY
The net income has dropped by 83% year-on-year but it rose by 19% since the previous quarter
The gross profit has plunged by 84% YoY
PRPH's revenue has dropped by 75% year-on-year and by 33% since the previous quarter

Key stats

What are the main financial stats of PRPH
Market
Shares outstanding
41.54M
Market cap
$13.31M
Enterprise value
$27.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.96
Earnings
Revenue
$4.57M
Gross profit
$809,000
Operating income
-$34.04M
Net income
-$43.13M
EBIT
-$30M
EBITDA
-$23.55M
Free cash flow
-$15.49M
Per share
EPS
-$2.16
EPS diluted
-$2.16
Free cash flow per share
-$0.44
Book value per share
$0.63
Revenue per share
$0.13
TBVPS
$1.02
Balance sheet
Total assets
$50.11M
Total liabilities
$34.99M
Debt
$14.01M
Equity
$15.12M
Working capital
$718,000
Liquidity
Debt to equity
0.93
Current ratio
1.03
Quick ratio
0.84
Net debt/EBITDA
-0.59
Margins
EBITDA margin
-515.6%
Gross margin
17.7%
Net margin
-944.4%
Operating margin
-745.3%
Efficiency
Return on assets
-57.7%
Return on equity
-164.8%
Return on invested capital
-55.7%
Return on capital employed
-115.1%
Return on sales
-656.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRPH stock price

How has the ProPhase Labs stock price performed over time
Intraday
4.36%
1 week
-17.21%
1 month
-9.29%
1 year
-93.99%
YTD
-57.68%
QTD
-20.75%

Financial performance

How have ProPhase Labs's revenue and profit performed over time
Revenue
$4.57M
Gross profit
$809,000
Operating income
-$34.04M
Net income
-$43.13M
Gross margin
17.7%
Net margin
-944.4%
PRPH financials
The gross profit has plunged by 84% YoY
The net income has dropped by 83% year-on-year but it rose by 19% since the previous quarter
PRPH's revenue has dropped by 75% year-on-year and by 33% since the previous quarter
The company's gross margin fell by 36% YoY

Price vs fundamentals

How does PRPH's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is ProPhase Labs's growth rate over time
PRPH growth chart

Valuation

What is ProPhase Labs stock price valuation
P/E
N/A
P/B
0.51
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.96
Valuation vs average
Price to earnings (P/E)
The EPS has plunged by 58% YoY but it has increased by 17% from the previous quarter
Price to book (P/B)
ProPhase Labs's equity has surged by 106% QoQ but it has shrunk by 66% YoY
PRPH's price to book (P/B) is 79% lower than its 5-year quarterly average of 2.4 and 66% lower than its last 4 quarters average of 1.5
Price to sales (P/S)
PRPH's revenue has dropped by 75% year-on-year and by 33% since the previous quarter
The P/S is 74% lower than the last 4 quarters average of 9.6 and 37% lower than the 5-year quarterly average of 3.9

Efficiency

How efficient is ProPhase Labs business performance
ProPhase Labs's return on assets has shrunk by 123% YoY but it has increased by 8% QoQ
The return on invested capital has declined by 30% year-on-year but it is up by 15% since the previous quarter
PRPH's return on equity is down by 3.8% since the previous quarter
The ROS has decreased by 3.8% from the previous quarter

Dividends

What is PRPH's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did ProPhase Labs financials performed over time
Assets vs liabilities
PRPH's total assets is 43% greater than its total liabilities
The company's quick ratio fell by 45% YoY but it rose by 29% QoQ
ProPhase Labs's current ratio has decreased by 45% YoY but it has increased by 8% from the previous quarter
Debt vs equity
The debt is 7% less than the equity
ProPhase Labs's equity has surged by 106% QoQ but it has shrunk by 66% YoY
PRPH's debt to equity has surged by 79% year-on-year but it has dropped by 72% since the previous quarter
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.